A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine
- 1 February 2008
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (2), 348-358
- https://doi.org/10.1128/cvi.00440-07
Abstract
Live-virus vaccines for smallpox are effective but have risks that are no longer acceptable for routine use in populations at minimal risk of infection. We have developed a mucosal, killed-vaccinia virus (VV) vaccine based on antimicrobial nanoemulsion (NE) of soybean oil and detergent. Incubation of VV with 10% NE for at least 60 min causes the complete disruption and inactivation of VV. Simple mixtures of NE and VV (Western Reserve serotype) (VV/NE) applied to the nares of mice resulted in both systemic and mucosal anti-VV immunity, virus-neutralizing antibodies, and Th1-biased cellular responses. Nasal vaccination with VV/NE vaccine produced protection against lethal infection equal to vaccination by scarification, with 100% survival after challenge with 77 times the 50% lethal dose of live VV. However, animals protected with VV/NE immunization did after virus challenge have clinical symptoms more extensive than animals vaccinated by scarification. VV/NE-based vaccines are highly immunogenic and induce protective mucosal and systemic immunity without the need for an inflammatory adjuvant or infection with live virus.This publication has 43 references indexed in Scilit:
- Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responsesThe Journal of Experimental Medicine, 2007
- Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccineVaccine, 2007
- The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation programVaccine, 2005
- Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trialThe Lancet, 2005
- Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating densityJournal of Controlled Release, 2004
- Improved Assay To Detect Neutralizing Antibody following Vaccination with Diluted or Undiluted Vaccinia (Dryvax) VaccineJournal of Clinical Microbiology, 2003
- Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living MiceJournal of Virology, 2002
- Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign EpitopeJournal of Virology, 2002
- A Novel Surfactant Nanoemulsion with Broad‐Spectrum Sporicidal Activity againstBacillusSpeciesThe Journal of Infectious Diseases, 1999
- Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humansJournal of General Virology, 1993